Table 2.

Adjusted effects of Na level on 90-day adverse outcomes (death or LT) in all patients (n = 3880)

	Number of 90-day adverse outcomes (percentage)	OR, 95% CI, p value	OR, 95% CI, p value	OR, 95% CI, p value	OR, 95% CI, p value
		Model I	Model II	Model III	Model IV
Na (continuous)	712 (18.35)	0.88 (0.87,0.90) < 0.001	0.90 (0.88,0.91) < 0.001	0.91 (0.89,0.92) < 0.001	0.95 (0.93,0.97) < 0.001
Na-categorical
(Na 135–145 mmol/L)	398 (13.5)	1	1	1	1
(Na > 145 mmol/L)	14 (17.5)	1.37 (1.02,1.83)0.039	1.30 (0.72,2.36)0.386	0.91 (0.89,1.85)0.991	1.21 (0.63,2.34)0.565
(Na 120–135 mmol/L)	286 (35.2)	3.49 (2.92,4.18) < 0.001	3.02 (2.52,3.63) < 0.001	2.56 (2.12,3.09) < 0.001	1.72 (1.39,2.13) < 0.001
(Na ≤ 120 mmol/L)	14 (50)	6.44 (3.05,13.60) < 0.001	5.19 (2.45,11.03) < 0.001	4.41 (2.03,9.58) < 0.001	2.36 (0.98,5.67)0.056
p value for trend*		< 0.001	< 0.001	< 0.001	< 0.001
Na (continuous 5 mmol/L decrease)		0.54 (0.50,0.59) < 0.001	0.58, (0.53,0.63) < 0.001	0.62, (0.57,0.67) < 0.001	0.76 (0.70,0.84) < 0.001
Na (continuous 10 mmol/L decrease)		0.29 (0.25,0.34) < 0.001	0.33 (0.28,0.39) < 0.001	0.38 (0.32,0.45) < 0.001	0.58 (0.49,0.70) < 0.001

Model I Un-adjusted;

Model II Adjusted for age, sex, cirrhosis;

Model III Adjusted for age, sex, cirrhosis, HE, ascites, infection;

Model IV Adjusted for age, sex, cirrhosis, HE, ascites, infection, TBIL, INR, CR;

CI confidence interval

^*Test for trend based on variables containing median value for each group